KUALA LUMPUR: Pharmaniaga Bhd expects to deliver new product offerings for both local and overseas markets for the coming years ahead that will strengthen earnings potential.
The company said it was well-prepared to tap opportunities, amid encouraging backdrop from the government’s total allocation of RM27 billion in healthcare services.
Pharmaniaga’s net profit in the third-quarter ended September 30, 2017, dropped to RM3.58 million from RM13.06 million a year ago. This was mainly attributable to lower off-take for in-house products.
In an exchange filing today, the company said its revenue had risen 11.51 per cent to RM574.50 million from RM515.22 million.
This was due to increased orders from government hospitals and double-digit growth from the group’s Indonesia operations.
Pharmaniaga announced an interim dividend of five sen for the financial year ending December 31, 2017, payable on December 15.